Taken together, the DynaTag p53 landscapes acquired in SCLC suggest a gain-of-function for p53  R248Q in response to chemotherapy at promoters of signature genes related EMT, thus highlighting the potential of DynaTag for uncovering in vivo significant TF alterations. This evidence concerns the gene TP53 and small cell lung carcinoma.